Found 338 clinical trials
Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objectives of this study are to evaluate the safety and efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in
- 2136 views
- 26 Apr, 2019
- 1 location
Ulcerative Colitis Research Study
Local doctors are looking for people with Ulcerative Colitis for clinical research studies of an investigational medication. Must be receiving treatment for Ulcerative Colitis
- 954 views
- 07 Nov, 2020
- 1 location
Ulcerative Colitis (UC) Study at ClinSearch
Ulcerative Colitis (UC) is another form of inflammatory bowel disease (IBS). Unlike Crohn’s, which can affect any part of the digestive tract, UC only affects the colon and rectum.
- 85 views
- 23 Mar, 2022
- 1 location
A Phase 2, Double-Blind, Dose-Ranging, Placebo-Controlled Study With Open-Label Extension to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
This Phase 2 study is designed to evaluate the efficacy and safety of itacitinib in men and women with moderate to severe UC. The study consists of Part A and Part B, which consist of 12 weeks of double-blind, randomized, placebo-controlled treatment periods followed by 40 weeks open label extension …
- 65 views
- 10 May, 2022
- 5 locations
Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis (ELEVATE UC 52)
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderately to severely active ulcerative colitis.
- 98 views
- 08 Dec, 2020
- 1 location
MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS
ULCERATIVE COLITIS IS AN INFLAMMATORY BOWEL DISEASE THAT CAUSES LONG-LASTING INFLAMMATION AND ULCERS (SORES) IN YOUR DIGESTIVE TRACT.
- 99 views
- 23 Nov, 2020
- 1 location
A3921210 OVATION
This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US patients with prior TNFi failure or intolerance will be enrolled. Outside of the US, TNFi naïve and TNFi experienced patients will be enrolled.All eligible participants …
- 41 views
- 05 Jul, 2022
- 9 locations